Influenza immunology evaluation and correlates of protection: a focus on vaccines

Expert Review of Vaccines

Volumn 15, Issue 8, 2016, Pages 967-976

  Trombetta, Claudia Maria ^a   Montomoli, Emanuele ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b VisMederi Srl   (Italy)

Author keywords

Correlates of protection; Guidelines on influenza vaccines; Haemagglutination inhibition titer; Immunological assays; Influenza vaccines

Indexed keywords

AVIAN INFLUENZA VACCINE; INFLUENZA VACCINE; BIOLOGICAL MARKER; VIRUS ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOASSAY; IMMUNOLOGY; INFLUENZA, HUMAN; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, VIRAL; BIOMARKERS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOASSAY; INFLUENZA VACCINES; INFLUENZA, HUMAN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84961675522     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1164046     Document Type: Article

References (125)

1. D.Onions, W.Egan, R.Jarrett, et al. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals. 2010;38(5):544–51.
2. E.Montomoli, B.Capecchi, K.Hoschler Correlates of Protection Against Influenza. In: S.B.Ag, editor. Influenza Vaccines for the Future. Basel: Springer: 2011.
3. S.Sridhar, K.A.Brokstad, R.J.Cox. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel). 2015;3(2):373–389.
4. I.Manini, A.Domnich, D.Amicizia, et al. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines. 2015;14(6):789–804.
5. D.Hobson, R.L.Curry, A.S.Beare, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–777.
6. CPMP. Note for guidance on harmonisation of requirements for influenza vaccines. London: The European Agency for the Evaluation of Medicinal Products; 1997.
7. S.A.Plotkin, P.B.Gilbert. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615–1617.
8. L.Qin, P.B.Gilbert, L.Corey, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007;196(9):1304–1312.
9. C.Hannoun, F.Megas, J.Piercy. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1–2):133–138.
10. S.A.Plotkin. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409.
11. R.Al-Khayatt, R.Jennings, C.W.Potter. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond). 1984;93(2):301–312.
12. J.C.de Jong, A.M.Palache, W.E.Beyer, et al. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73.
13. L.Coudeville, F.Bailleux, B.Riche, et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
14. L.Coudeville, P.Andre, F.Bailleux, et al. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin. 2010;6(10):841–848.
15. S.Black, U.Nicolay, T.Vesikari, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30(12):1081–5.• Inadequacy of current correlates of protection in children.
16. M.Granström, A.C.Voordouw. Registration of influenza vaccines for children in Europe. Vaccine. 2011;29(43):7572–7575.
17. S.E.Ohmit, J.G.Petrie, R.T.Cross, et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204(12):1879–1885.
18. C.Van Els, S.Mjaaland, L.Naess, et al. Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother. 2014;10(7):1935–1948.
19. J.M.Katz, K.Hancock, X.Xu. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669–683.
20. J.M.Wood, D.Melzack, R.W.Newman, et al. A single radial haemolysis assay for antibody to H5 haemagglutinin. Int Congress Ser. 2001;1219:761–766.
21. P.C.Soema, R.Kompier, J.P.Amorij, et al. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–63.• Interesting review on the current status and novel developments in influenza vaccine field from different viewpoints.
22. A.Goodeve, C.W.Potter, A.Clark, et al. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond). 1983;90(1):107–115.
23. WHO. Serological detection of avian influenza A(H7N9) virus infections by modified horde red blood cells haemagglutination-inhibition assay. China: World Health Organization; 2013. p. 1–11.
24. A.Reber, J.Katz. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12(5):519–536.
25. J.M.Wood, E.Montomoli, R.W.Newman, et al. Collaborative study on influenza vaccine clinical trial serology - part 2: reproducibility study. Pharmeur Bio Sci Notes. 2011;2011(1):36–54.
26. I.Stephenson, A.Heath, D.Major, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis. 2009;15(8):1252–1259.
27. D.L.Noah, H.Hill, D.Hines, et al. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol. 2009;16(4):558–566.
28. W.E.Beyer, A.M.Palache, G.Lüchters, et al. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 2004;103(1–2):125–132.
29. W.E.Beyer, A.M.Palache, M.J.Sprenger, et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine. 1996;14(14):1331–1339.
30. G.C.Schild, M.S.Pereira, P.Chakraverty. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ. 1975;52(1):43–50.
31. P.S.Morley, L.K.Hanson, J.R.Bogdan, et al. The relationship between single radial hemolysis, hemagglutination inhibition, and virus neutralization assays used to detect antibodies specific for equine influenza viruses. Vet Microbiol. 1995;45(1):81–92.
32. M.Clarke, J.Boustred, V.Seagroatt, et al. The use of single-radial-haemolysis for rubella antibody studies. J Hyg (Lond). 1977;79(3):355–364.
33. K.A.Callow, A.S.Beare. Measurement of antibody to influenza virus neuraminidase by single radial hemolysis in agarose gels. Infect Immun. 1976;13(1):1–8.
34. C.M.Trombetta, D.Perini, L.Vitale, et al. Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. J Immunol Methods. 2015;422:95–101.
35. K.Farrohi, F.K.Farrohi, G.R.Noble, et al. Evaluation of the single radial hemolysis test for measuring hemagglutinin- and neuraminidase-specific antibodies to H3N2 influenza strains and antibodies to influenza B. J Clin Microbiol. 1977;5(3):353–360.
36. R.E.Fulton, V.L.DiNinno, R.I.Frank, et al. Single radial hemolysis test for quantitation of complement-fixing antibodies to non-hemagglutinating viruses. J Clin Microbiol. 1984;20(2):248–254.
37. A.C.Goodeve, R.Jennings, C.W.Potter. The use of the single radial haemolysis test for assessing antibody response and protective antibody levels in an influenza B vaccine study. J Biol Stand. 1983;11(4):289–296.
38. T.Rowe, R.A.Abernathy, J.Hu-Primmer, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937–943.
39. A.Delem. Serum SRH antibody level as a measure of the immunity against natural and artificial A/Victoria/3/75 infections. Dev Biol Stand. 1977;39:391–396.
40. J.M.Wood, R.E.Gaines-Das, J.Taylor, et al. Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994;12(2):167–174.
41. G.Kayali, S.F.Setterquist, A.W.Capuano, et al. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J Clin Virol. 2008;43(1):73–78.
42. WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. Geneva: World Health Organization; 2007. p. 1–28.
43. R.Wagner, C.Göpfert, J.Hammann, et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine. 2012;30(27):4113–4122.
44. V.Veguilla, K.Hancock, J.Schiffer, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol. 2011;49(6):2210–2215.
45. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011. p. 1–137.
46. M.V.van der Velden, G.Aichinger, E.M.Pöllabauer, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine. 2012;30(43):6127–6135.
47. F.Ansaldi, S.Bacilieri, D.Amicizia, et al. Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis. J Med Virol. 2004;74(1):141–146.
48. I.Stephenson, R.G.Das, J.M.Wood, et al. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine. 2007;25(20):4056–4063.
49. M.K.Howard, N.Sabarth, H.Savidis-Dacho, et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One. 2011;6(8):e23791.
50. H.J.Ehrlich, M.Muller, H.M.Oh, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008;358(24):2573–2584.
51. R.J.Cox, G.Pedersen, A.S.Madhun, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine. 2011;29(45):8049–8059.
52. G.Galli, D.Medini, E.Borgogni, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A. 2009;106(10):3877–3882.
53. R.Allwinn, J.Geiler, A.Berger, et al. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. 2010;199(2):117–121.
54. E.Miller, K.Hoschler, P.Hardelid, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100–1108.
55. H.Hakim, K.J.Allison, L.A.Van De Velde, et al. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine. 2012;30(5):879–885.
56. W.E.Adamson, E.C.McGregor, K.Kavanagh, et al. Population exposure to a novel influenza A virus over three waves of infection. J Clin Virol. 2011;52(4):300–303.
57. C.P.Verschoor, P.Singh, M.L.Russell, et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One. 2015;10(6):e0131531.
58. T.K.Tsang, S.Cauchemez, R.A.Perera, et al. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis. 2014;210(5):684–692.
59. C.M.Trombetta, D.Perini, S.Mather, et al. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines. 2014;2(4):707–734.
60. G.W.Carnell, F.Ferrara, K.Grehan, et al. Pseudotype-based neutralization assays for influenza: a systematic analysis. Front Immunol. 2015;6:161.
61. Z.Zakay-Rones. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines. 2010;9(12):1423–1439.
62. J.A.McCullers, V.C.Huber. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother. 2012;8(1):34–44.
63. E.D.Kilbourne, R.B.Couch, J.A.Kasel, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine. 1995;13(18):1799–1803.
64. E.D.Kilbourne, W.G.Laver, J.L.Schulman, et al. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol. 1968;2(4):281–288.
65. J.L.Schulman, M.Khakpour, E.D.Kilbourne. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol. 1968;2(8):778–786.
66. E.D.Kilbourne, B.E.Johansson, B.Grajower. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A. 1990;87(2):786–790.
67. B.E.Johansson, D.J.Bucher, E.D.Kilbourne. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol. 1989;63(3):1239–1246.
68. R.B.Couch, R.L.Atmar, L.M.Franco, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013;207(6):974–981.
69. S.Rockman, L.E.Brown, I.G.Barr, et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol. 2013;87(6):3053–3061.
70. A.S.Monto, J.G.Petrie, R.T.Cross, et al. Antibody to Influenza Virus Neuraminidase: an Independent Correlate of Protection. J Infect Dis. 2015;212(8):1191–1199.
71. C.R.Lambré, H.Terzidis, A.Greffard, et al. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods. 1990;135(1–2):49–57.
72. EMA. Report from scientific workshop on serology assays and correlates of protection for influenza vaccines. London: European Medicines Agency; 2010. p. 1–32.
73. R.Fritz, N.Sabarth, S.Kiermayr, et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis. 2012;205(1):28–34.
74. B.R.Murphy, E.L.Tierney, B.A.Barbour, et al. Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines. Infect Immun. 1980;29(2):342–347.
75. R.Turner, J.L.Lathey, L.P.Van Voris, et al. Serological diagnosis of influenza B virus infection: comparison of an enzyme-linked immunosorbent assay and the hemagglutination inhibition test. J Clin Microbiol. 1982;15(5):824–829.
76. M.M.Alvarez, F.López-Pacheco, J.M.Aguilar-Yañez, et al. Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method. PLoS One. 2010;5(4):e10176.
77. R.Jennings, T.Smith, C.W.Potter. Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study. Med Microbiol Immunol. 1981;169(4):247–258.
78. R.J.Cox, K.A.Brokstad, P.Ogra. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59(1):1–15.
79. P.G.Thomas, R.Keating, D.J.Hulse-Post, et al. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006;12(1):48–54.
80. P.C.Soema, E.van Riet, G.Kersten, et al. Development of cross-protective influenza a vaccines based on cellular responses. Front Immunol. 2015;6:237.
81. N.Svitek, E.L.Taracha, R.Saya, et al. Analysis of the Cellular Immune Responses to Vaccines. Methods Mol Biol. 2016;1349(p):247–262.
82. L.Coughlan, T.Lambe. Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. Vaccines (Basel). 2015;3(2):293–319.• Useful summary of cellular immunity concept and related techniques.
83. WHO. Correlates of vaccine-induced protection: methods and implications. Geneva: World Health Organization; 2013. p. 1–65.
84. A.Podda. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19(17–19):2673–2680.
85. W.E.Beyer, A.M.Palache, J.C.de Jong, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002;20(9–10):1340–1353.
86. P.N.Barrett, G.Berezuk, S.Fritsch, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011;377(9767):751–759.
87. S.De Donato, D.Granoff, M.Minutello, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine. 1999;17(23–24):3094–3101.
88. T.Vesikari, N.Groth, A.Karvonen, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27(45):6291–6295.
89. R.Gasparini, T.Pozzi, E.Montomoli, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol. 2001;17(2):135–140.
90. M.Pellegrini, U.Nicolay, K.Lindert, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959–6965.
91. M.Knuf, G.Leroux-Roels, H.Rümke, et al. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children. Hum Vaccin Immunother. 2015;11(2):358–376.
92. C.E.Oh, J.Lee, J.H.Kang, et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine. 2010;28(36):5857–5863.
93. M.Knuf, G.Leroux-Roels, H.C.Rümke, et al. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine. 2015;33(1):174–181.
94. T.Nolan, L.Bravo, A.Ceballos, et al. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children. Vaccine. 2014;32(46):6146–6156.
95. M.Knuf, G.Leroux-Roels, H.C.Rümke, et al. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6–35 months of age. Pediatr Infect Dis J. 2014;33(12):e320–9.
96. T.Nolan, P.Izurieta, B.W.Lee, et al. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age. J Infect Dis. 2014;210(11):1800–1810.
97. A.Örtqvist, R.Bennet, J.Hamrin, et al. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. Vaccine. 2015;33(22):2558–2561.
98. P.Izurieta, M.J.Uy-Aragon, M.Dramé, et al. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age. Pediatr Infect Dis J. 2016;35(2):e35–47.
99. J.Garcia-Sicilia, J.Arístegui, F.Omeñaca, et al. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies. Hum Vaccin Immunother. 2015;11(10):2359–2369.
100. P.Gillard, D.Giet, S.Heijmans, et al. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study. Trials. 2014;15:419.
101. K.S.Reisinger, S.J.Holmes, P.Pedotti, et al. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Hum Vaccin Immunother. 2014;10(8):2395–2407.
102. S.E.Frey, M.R.Reyes, H.Reynales, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027–5034.
103. D.P.Greenberg, C.A.Robertson, M.J.Noss, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770–776.
104. J.Beran, M.Peeters, W.Dewé, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224.
105. L.Wang, V.Chandrasekaran, J.B.Domachowske, et al. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. J Pediatric Infect Dis Soc. 2015:pii:piv041. [Epub ahead of print]
106. J.M.Langley, L.Wang, N.Aggarwal, et al. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. J Pediatric Infect Dis Soc. 2015;4(3):242–251.
107. J.C.Tinoco, N.Pavia-Ruz, A.Cruz-Valdez, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine. 2014;32(13):1480–1487.
108. C.S.Ambrose, X.Wu, R.B.Belshe. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29(9):806–811.
109. R.B.Belshe, K.M.Edwards, T.Vesikari, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685–696.
110. D.F.Hoft, E.Babusis, S.Worku, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845–853.
111. M.L.Clements, R.F.Betts, E.L.Tierney, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986;24(1):157–160.
112. J.G.Petrie, S.E.Ohmit, E.Johnson, et al. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011;203(9):1309–1315.
113. CHMP. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. London: European Medicines Agency. EMEA/CHMP/VWP/263499/2006; 2006. p. 1–11.
114. Report. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccines development, Bethesda, Maryland, US, December 10–11, 2007. 2007. Vaccine.
115. EMA. Guideline on influenza vaccines. Non-clinical and clinical module. Draft. London: European Medicines Agency; 2014.
116. D.C.Powers, E.D.Kilbourne, B.E.Johansson. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol. 1996;3(5):511–516.
117. M.R.Sandbulte, G.S.Jimenez, A.C.Boon, et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007;4(2):e59.
118. J.E.McElhaney. Influenza vaccine responses in older adults. Ageing Res Rev. 2011;10(3):379–388.
119. A.Impagliazzo, F.Milder, H.Kuipers, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349(6254):1301–6.•• New prospective for the development of a universal vaccines.
120. H.M.Yassine, J.C.Boyington, P.M.McTamney, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21(9):1065–70.•• Important finding on the protective immunity induced by hemagglutinin stem nanoparticles in mice and ferrets.
121. Z.Chen, L.Kim, K.Subbarao, et al. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine. 2012;30(15):2516–2522.
122. J.D.Easterbrook, L.M.Schwartzman, J.Gao, et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology. 2012;432(1):39–44.
123. A.Osterhaus, R.Fouchier, G.Rimmelzwaan. Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2766–2773.
124. J.H.Kreijtz, G.de Mutsert, C.A.van Baalen, et al. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol. 2008;82(11):5161–5166.
125. S.Sridhar, S.Begom, A.Bermingham, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19(10):1305–1312.